Table 1 Characteristics by standard flow cytometric MRD status in pre-relapse samples.
All n = 136 | Flow MRD negative n = 47 | Flow MRD positive | |||
|---|---|---|---|---|---|
All n = 89 | < 0.1% n = 17 | ≥ 0.1% n = 72 | |||
Interval between MRD sample and relapse Months, median [IQR] | 2.45 [1.74–3.08] | 2.77 [2.30–3.43] | 2.27 [1.43–2.80] | 2.80 [2.07–3.43] | 2.12 [1.39–2.71] |
Diagnostic Genetics | |||||
Adverse cytogenetics or TP53 mutated | 46 (36%) | 14 (34%) | 32 (36%) | 9 (53%) | 23 (32%) |
FLT3 mutated | 29 (22.5%) | 13 (32%) | 16 (18%) | 4 (23.5%) | 12 (17%) |
MDS-related mutations | 22 (17%) | 6 (15%) | 16 (18%) | 1 (6%) | 15 (21%) |
Other | 32 (25%) | 8 (19.5%) | 24 (27%) | 3 (18%) | 21 (30%) |
NPM1 mutated | 5 | 1 | 4 | 4 | 0 |
(FLT3 wild type) | |||||
Unknown | 7 | 6 | 1 | 0 | 1 |
Treatment Stage | |||||
Post chemotherapy | 48 (35%) | 10 (21%) | 38 (43%) | 5 (29%) | 33 (46%) |
Post allograft | 88 (64.7%) | 37 (79%) | 51 (57%) | 12 (71%) | 39 (54%) |
Relapse major blast Immunophenotype | |||||
CD34+ | 109 (80%) | 44 (94%) | 65 (73%) | 12 (71%) | 53 (74%) |
CD34-CD117+ | 21 (15%) | 3 (6%) | 18 (20%) | 5 (29%) | 13 (18%) |
Monocytic | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Other | 6 (4%) | 0 (0%) | 6 (7%) | 0 (0%) | 6 (8%) |
